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Abstract
Background: Leptospirosis is a potentially lethal zoonosis mainly affecting low-resource tropical countries,
including Peru and its neighbouring countries. Timely diagnosis of leptospirosis is critical but may be challenging in
the regions where it is most prevalent. The serodiagnostic gold standard microagglutination test (MAT) may be
technically prohibitive. Our objective in this study was to assess the sensitivity, specificity, and predictive value of an
IgM antibody capture enzyme-linked immunoassay (MAC-ELISA) derived from the M20 strain of Leptospira
interrogans serovar Copenhageni (M20) by comparison to MAT, which was used as the gold standard method of
diagnosis.
Methods: Acute and convalescent sera from participants participating in a passive febrile surveillance study in
multiple regions of Peru were tested by both IgM MAC-ELISA and MAT. The sensitivity, specificity, positive and
negative predictive value (PPV, NPV) of the MAC-ELISA assay for acute, convalescent and paired sera by comparison
to MAT were calculated.
Results: The sensitivity, specificity, PPV and NPV of the MAC-ELISA assay for acute sera were 92.3%, 56.0%, 35.3%
and 96.6% respectively. For convalescent sera, the sensitivity, specificity, PPV and NPV of the MAC-ELISA assay were
93.3%, 51.5%, 63.6% and 89.5% respectively. For paired sera, the sensitivity, specificity, PPV and NPV of the MAC-
ELISA assay were 93.6%, 37.5%, 59.2%, 85.7% respectively.
Conclusions: The M20 MAC-ELISA assay performed with a high sensitivity and low specificity in the acute phase of
illness. Sensitivity was similar as compared with MAT in the convalescent phase and specificity remained low. Paired
sera were the most sensitive but least specific by comparison to MAT serodiagnosis. NPV for acute, convalescent
and paired sera was high. The limited specificity and high sensitivity of the MAC-ELISA IgM suggests that it would
be most valuable to exclude leptospirosis in low-resource regions that lack immediate access to definitive reference
laboratory techniques such as MAT.
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Background
Leptospirosis is a common and potentially lethal zoonotic
disease with a world-wide distribution. It has a prevalence
ranging from under 1 per 100,000 persons in developed
temperate countries to over 100 per 100,000 persons
in tropical developing regions [1]. As such, the burden
of morbidity and mortality from leptospirosis occurs
predominately in low-to-middle income countries in the
tropics or subtropics [2].
Leptospira interrogans, the prinicipal pathogenic species
of the genus, is an aerobic spirochete species with a wide
range of animal reservoirs, including rodents and livestock
[3,4]. Human inoculation via skin breaches or mucosal
surfaces may occur upon exposure directly to animal
urine or indirectly via contact with waste-contaminated
water [5]. High risk groups for infection therefore may
include veterinarians, abattoir workers, farmers and those
living in riverside communities and areas of high rainfall
[4,6]. In recent decades, outbreaks have been noted in
adventure travellers, military personnel and triathlon
competitors [1,7,8]. Leptospirosis may also cause significant
morbidity in regions prone to flooding, even in developed
countries with excellent healthcare infrastructure [9].
The clinical features of leptospirosis are often non-
specific. Even with a compatible exposure history, the
differential diagnosis may be broad [2,6]. Leptospirosis
may progress rapidly from an apparently mild illness to
life-threatening manifestations such as pulmonary haemor-
rhage, jaundice, acute kidney injury and meningoencephal-
itis. Such severe forms of leptospirosis have poor outcomes
and carry a worse prognosis in those who do not receive
prompt treatment [4].
For these reasons, a timely and accurate laboratory
diagnosis is essential in the approach to suspected lepto-
spirosis cases. This remains challenging, particularly in the
very regions where the disease is most prevalent. Darkfield
microscopy is inaccurate [2,3] and blood or urine cultures
are slow and insensitive [3,4]. Newer molecular methods
such as PCR and loop-mediated isothermal amplification
are emerging as promising next-generation diagnostic tools
but have not been widely validated. Moreover, their cost
and technical expertise may inhibit their use in developing
countries [5,10].
Serological methods remain the mainstay of diagnosis
for leptospirosis [2,5]. Microagglutination testing (MAT) is
still the most widely used serological assay and is regarded
as the ‘gold standard’ of serodiagnosis, albeit with several
limitations. The technical skill required for MAT limits its
use in many non-reference laboratories, particularly in
low-to-middle income countries [5]. Additionally, the need
for a live panel of leptospires in MAT is a laboratory
biohazard, and maintaining a geographically appropriate
range of serovars may be challenging [11]. Other limita-
tions include a limited sensitivity during the early
phases of illness [3], inter-laboratory variation due to
subjective interpretation of agglutination and difficulty
in standardisation [3,6].
IgM antibody capture ELISA (MAC-ELISA) assays may
offer a cheaper, simpler alternative method of serodiagnosis
which can be standardised and may be more sensitive
in the acute phase of illness. Other ELISA-IgM assays,
including dipstick IgM, dot-ELISA IgM and commercial
IgM ELISA have been validated in Asia, North America,
Latin America and the Pacific [12-14]. However there is a
paucity of validation studies carried out in Peru [15], a
country which experiences a high burden of leptospirosis,
with seropositivity rates ranging up to 28% in regions such
as the Amazon basin [15].
The objective of this study was to assess the sensitivity,
specificity and predictive value of an IgM antibody cap-
ture enzyme linked immunoassay (MAC-ELISA) derived
from the (M20) strain of Leptospira interrogans serovar
Copenhageni M20 by comparison to MAT, which was used
as the gold standard method of diagnosis.
Methods
An overview flowchart of the materials and methods is
presented in Figure 1.
Setting, study population and enrolment
In 1990, the United States Naval Medical Research Unit
No. 6 (NAMRU-6) established a passive surveillance
network for the study of acute febrile syndromes in the
Peruvian Amazon, with expansion into Bolivia, Paraguay,
and other regions of Peru in 2000. Specific details of this
network have been previously described [16]. In this
leptospirosis IgM MAC-ELISA validation study, patients
aged five years or more with fever equal to or greater than
38.0°C for equal to or less than 7 days who presented for
medical care at local hospitals or outpatient clinics in Peru
(Iquitos, Yurimaguas, Madre de Dios, Junín, Tumbes)
between January 2006 and February 2008 were invited
to participate.
Patients were ineligible to participate if a clinically identi-
fiable focus of infection was present. A clinically identifiable
focus of infection included acute otitis media, sinusitis,
purulent pharyngitis, cellulitis, acute urinary tract infection,
dental caries, septic arthritis, pneumonia, pelvic inflamma-
tory illness or peritonitis. Identification of malaria on blood
films was not an exclusion criterion, as asymptomatic
Plasmodium parasitaemia is well-described in endemic
regions of Peru [17] and multiple etiologies of acute febrile
illness have been detected in prior studies in the Amazon
basin [18,19].
Study protocols (NMRCD.2000.0006 [Peru], NMRCD.
2000.0008 [Bolivia], and NMRCD.2005.0008 [Paraguay])
were approved by the Naval Medical Research Center
Institutional Review Board (Bethesda, Maryland, USA)
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in compliance with all U.S. Federal regulations governing
the protection of human subjects. In addition, ethical
review and approval was received from authorities in
Peru (Dirección General de Epidemiología, Lima). Written
consent was obtained from patients 18 years of age and
older. For patients younger than 18 years, written consent
was obtained from a parent or legal guardian. Additionally,
written assent was required from patients between 8 and
17 years of age.
Measures and procedures
Acute blood samples were obtained at the time of initial
presentation for medical care by trained study personnel.
Convalescent specimens were obtained between 10 and
21 days later. ‘Paired samples’ were defined as an acute
and a convalescent sample of the same participant.
Serum was separated from whole blood samples and
divided into 4 aliquots, which were stored at −70°C.
Samples were then transported in liquid nitrogen or on
dry ice to Lima for testing by MAC-ELISA and MAT at the
main NAMRU-6 laboratory in Lima and the Instituto de
Medicina Tropical Alexander von Humboldt (Universidad
Peruana Cayetano Heredia, Lima, Peru), respectively.
Data on sociodemographic characteristics (namely age
and sex) were collected by face-to-face interview with
study personnel.
Validation of ELISA MAC IgM in study sample ELISA MAC IgM assay development  
using archived sera controls 
MAC ELISA IgM assay designed 
MAC ELISA IgM optical density (OD) 
cut-off calculated by ROC after  
performing ELISA MAC IgM  on 
archived sera controls known to be 
Leptospirapositive (18 sera) or 
negative (50 sera) by MAT 
Enrolment of study participants with 
fever of unknown cause using 
inclusion and exclusion criteria
Acute and convalescent sera drawn 
on those participants included in 
study
MAC ELISA IgM cross-reactivity with 
other pathogens determined by 
performing MAC ELISA IgM on 34 
archived sera from patients with 
other infections. When MAC-ELISA 
IgM positive, MAT performed to 
exclude Leptospiraco-infection 
After satisfactory performance with 
controls, MAC ELISA IgM then 
validated on study sample of 
patients with unknown febrile illness
MAC ELISA IgM and MAT performed 
on acute and convalescent sera. 
Positive acute or convalescent ELISA  
MAC IgM defined as OD reading 
above the determined cut-off at an  
analyte titre of ≥ 1:400 on serial  
dilutions of sera. Paired sera 
positivity defined as four-fold rise in 
titre or a positive acute or 
convalescent sera by above criteria
MAC ELISA IgM sensitivity, 
specificity, PPV and NPV determined 
for acute, convalescent and paired 
sera with MAT as gold standard
Figure 1 Overview of study methods.
Canal et al. BMC Infectious Diseases 2013, 13:438 Page 3 of 7
http://www.biomedcentral.com/1471-2334/13/438
Development of IgM MAC-ELISA assay
The IgM MAC-ELISA was developed using total antigen
of L. interrogans serovar Copenhageni (M20). The anti-
gen was developed in-house from culture specimens
using a total sonicated extract at a concentration of
4300 ug/ml. This strain was chosen as previous ecological
studies in Peru have implicated the L. interrogans serogroup
Icterohaemorrhagiae (the same serogroup as L.interrogans
serovar Copenhagi) as a common cause of human disease
in this region [20]. A previous validation of a commercial
L.biflexa antigen-based ELISA IgM assay in Peru showed
a poor sensitivity and thus this species was avoided in the
ELISA design [8].
Vinyl microplates were impregnated overnight with
AffiniPure F(ab’)2 fragment goat anti-human IgM, Fc5μ
in a 1:1000 dilution with PBS pH 7.4 (Jackson Immuno-
Research, West Grove, Pennsylvania, USA). Sera tar-
gets were diluted 1:100 with a sera diluting solution of
phosphate-buffered saline (PBS), Tween 20 (Sigma-Aldrich,
St Louis, Missouri, USA) and skim milk 5% (Difco), and
incubated at 37°C for one hour before washing. M20
in-house antigen was used in a 1:800 dilution with sera
diluting solution and incubated to 37°C for one hour
before washing. Unconjugated hyperimmune rabbit anti-
Leptospira biflexa IgG antibody (Accurate Chemical,
Westbury, New York, USA) was used at a 1:2000 dilution
with sera diluting solution and incubated at 37°C for one
hour before washing. L. interrogans serovar Copenhageni
(M20) rabbit IgG antibody was unavailable for use in
this region at the time of the study. Goat anti-rabbit IgG
(H+ L)-HRP (Bio-rad, Hercules, New York, USA) was used
as a conjugate at a 1:4000 dilution with sera diluting
solution and incubated at 37C for one hour before
washing. 2,2'-azino-di-3-ethylbenzthiazoline-6-sulphonate
(KPL, Gaithersburg, Maryland, USA) was used as a
chromogen and added to each well 15 minutes before
reading optical density (OD) by the VMax microplate
reader at 405 nm with a reference filter between 620 to
650 nm (Molecular Devices MDS Analytical Technologies,
Sunnyvale, California, USA).
Determination of MAC-ELISA optical density (OD) cut-off
OD cut-offs were determined using 50 banked Leptospira-
negative control sera from healthy subjects from Lima,
Peru and 18 banked positive control sera from Peruvian
patients with known MAT-confirmed leptospirosis
from the Instituto Nacional de Salud del Perú. These
sera were not taken from the study sample, but were
reference banked specimens. The cut-off point was
calculated using the receiver operator characteristic
curve (ROC) through the Data Statistical Package for
the Social Sciences (Version 17.0, IBM, New York,
New York, USA).
Assessment for MAC-ELISA assay cross-reactivity with
other pathogens
Archived banked sera specimens from 34 patients with
evidence of other infections were also used as negative
controls. These sera were not taken from the study sample,
but were archived reference banked specimens. Sera from
patients with a diagnosis of brucellosis (4 cases, diagnosis
by in-house culture and indentification), bartonellosis
(9 cases by in-house culture and gltA gene PCR assay
[21], yellow fever (1 case by in-house anti-yellow fever
IgM ELISA), dengue (1 case by in-house anti-dengue
IgM ELISA), Oropouche virus (1 case by in-house anti-
Oropouche IgM ELISA), Caraparo virus (1 case by in-
house anti-Caraparo IgM ELISA), Venezualan Equine
Virus (1 case by in-house anti-VEE IgM ELISA), P. vivax
(1 case by Giemsa peripheral blood smear), P. falciparum
(1 case by Giemsa peripheral blood smear), hepatitis A (3
cases by HAV-IgM ELISA by Beijing Wantai Biological
Pharmacy Enterprise), hepatitis B (2 cases by Microparticle
Enzyme Immunoassay, AxSYM Core, Abbott Laboratories,
IL, USA), HIV (3 cases by Vironostika HIV-1 antigen by
Biomerieux, Lyon, France; and INNO-LIA™ HIV I/II Score
by Innogenetics, Gent, Belgium) and Treponema pallidum
(6 cases by Rapid Plasma Reagin positive, confirmed
by SYPHAGEN Treponema pallidum Hemaglutination
Biokit/PRP NOSTICON II, Biomérieux, Lyon, France)
were tested by the leptospirosis MAC-ELISA assay to
assess for cross-reactivity between leptospirosis and these
other pathogens.
Sample testing by IgM MAC-ELISA
Acute, convalescent and paired sera samples were tested
by IgM MAC-ELISA assay at serial dilutions in order to
determine a quantitative measurement of IgM. Positivity
of acute and convalescent sera was defined as an ELISA
MAC IgM OD greater than the determined cut-off at
titres of ≥ 1:400. Positivity of paired sera was defined by
having a four-fold or greater increase in IgM titre, or by
an IgM-reactive acute or convalescent sample at a titre
of ≥ 1:400.
Sample testing by MAT
MAT was performed at the Instituto de Medicina Tropical
Alexander von Humboldt (Universidad Peruana Cayetano
Heredia, Lima, Peru) as previously described with modi-
fications based on local leptospirosis epidemiology [22].
A panel of 23 strains was employed: L. interrogans serovar
Australis (Ballico), L. interrogans serovar Autumnalis
(Akiyami), L. borgpetersenii serovar Ballum (Mus 127), L.
borgpetersenii serovar Ballum (S602), L. interrogans serovar
Bataviae (Van Tienen), L. interrogans serovar Bratislave (Jez
Bratislava), L. interrogans serovar Canicola (Hond Utrecht
IV), L. weilii serovar Celledoni (Celledoni), L. interrogans
serovar Copenhageni (M20), L.kischneri serovar Cynopteri
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(3522 C), L. interrogans serovar Djasiman (Djasiman), L.
santarosai serovar Georgia (LT 117), L. interrogans serovar
Grippotyphosa (Moskva V), L. borgpetersenii serovar Hardjo
(Hardjoprajitno), L. interrogans serovar Icterohaemorrhagiae
(RGA), L. borgpetersenii serovar Javanica (Veldrat Batavia
46), L. interrogans serovar Mankarso (Mankarso), L. noguchii
serovar Panama (CZ214K), L. interrogans serovar Pomona
(Pomona), L. interrogans serovar Pyrogenes (Salinem), L.
borgpetersenii serovar Tarassovi (Perepelitsin), L. interrogans
serovar Wolfii (3705) and L. licerasiae serovar Varillal (Var
010). For acute and convalescent sera, 50% cell agglutin-
ation for one or more serovars at a dilution of ≥ 1:400
was considered positive for this region. For paired sera,
a positive result was defined as a four-fold increase in titre
between acute and convalescent samples, or an acute or
convalescent sample with a titre of ≥ 1:400.
Validation of IgM MAC-ELISA
Acute and convalescent sera were tested by both IgM
MAC-ELISA and MAT, the latter of which served as the
gold standard for leptospirosis positivity. All IgM MAC-
ELISA and MAT data were entered into an electronic
database and analysed using STATA 12 (Stata Corp,
College Station, Texas, USA). The sensitivity, specificity,
and positive and negative predictive values (PPV, NPV) of
MAC-ELISA IgM for acute, convalescent and paired sera
samples were calculated.
Results
The OD cut-off value of the MAC-ELISA assay was
established at 0.299 with 100% sensitivity and 98% specifi-
city under the ROC curve. When tested against negative
control sera with other infections for cross-reactivity,
one HIV-positive serum (and none of the remaining 33
negative control sera) tested positive to leptospirosis by
MAC-ELISA assay. This HIV-positive serum was subse-
quently determined to be leptospirosis-negative by MAT
testing, thus excluding leptospirosis co-infection.
63 participants from the study sites were enrolled for
validation of the MAC-ELISA IgM assay between January
2006 and February 2008. Sociodemographic characteristics
of these participants are presented in Table 1. Of these
participants, 20.6% (13/63) were positive by MAT on acute
sera, 47.6% (30/63) were positive on convalescent sera and
49.2% (31/63) were positive on paired sera. 54.0% (34/63)
were positive by MAC-ELISA IgM on acute sera, 69.8%
(44/63) were positive on convalescent sera and 77.8%
(49/63) were positive on paired sera. 44.4% (28/63) of
patients were negative by MAT and MAC ELISA IgM on
acute sera. 26.9% (17/63) of patients were negative by
MAT and MAC ELISA IgM on convalescent sera. 19.0%
(12/63) of patients were negative by MAT and MAC
ELISA IgM on paired sera. The sensitivity, specificity, PPV
and NPV of the MAC-ELISA assay for acute, convalescent
and paired sera by comparison to MAT are presented in
Table 2.
Discussion
The study sample was predominantly young (median
age = 22), comparable to other studies in developed and
developing countries [15,23]. The majority of cases were
located in the Loreto district, an Amazonian region which
has high rainfall and suitable ecology for leptospirosis.
The town of Iquitos in particular is known to have a
notably high seroprevalence of leptospirosis in slum areas
[15]. As such, these study findings have reasonable
generalizability to other regions of the world which suffer
a high burden of Leptospira disease.
Our MAC-ELISA assay performed with a high sensitivity
and low specificity in the acute phase of illness. Sensitivity
was similar as compared with MAT in the convalescent
phase and specificity remained low. Paired sera were the
most sensitive but least specific by comparison to MAT
Table 1 Sex, location and age of study participants
n %






Madre de Dios 1 1.6
Tumbes (Tumbes) 4 6.3
Loreto (Yurimaguas) 9 14.3
Loreto (Iquitos) 46 73
Age (years)
Median 22
Range 9 - 58
aTown unknown in some participants.
Table 2 Accuracy of L. interrogans serovar Copenhageni
MAC ELISA IgM in diagnosis of leptospirosis compared to
microscopic agglutination testing in acute, convalescent
and paired sera
Sensitivity% Specificity% PPV% NPV%
(CI 95%) (CI 95%) (CI 95%) (CI 95%)
ELISA IgM, 92.3 56.0 35.3 96.6
Acute (85.7 - 98.9) (43.7 - 68.3) (23.5 - 47.1) (92.05 - 100)
ELISA IgM, 93.3 51.5 63.6 89.5
Convalescent (87.2 - 99.5) (39.2 - 63.9) (51.8 - 75.5) (81.9 - 97.1)
ELISA IgM, 93.6 37.5 59.2 85.7
Paired (87.5 - 99.6) (25.5 - 49.5) (47.1 - 71.3) (77.1 - 94.4)
MAC-ELISA, IgM antibody capture enzyme-linked immunoassay.
NPV, Negative Predictive Value, PPV, Positive Predictive Value.
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serodiagnosis. Negative predictive value for acute, conva-
lescent and paired sera was over 85%.
The sensitivity of this M20 MAC-ELISA IgM assay in
the acute phase, while high, may have been limited by
fundamental differences in MAT and ELISA techniques:
MAT detects both anti-Leptospira IgM and IgG [5],
whereas the MAC-ELISA detects solely IgM, and some
patients with prior exposure to Leptospira may develop
an early anamnestic IgG response. The limited specificity
of this MAC-ELISA assay may also be attributable to
persistent IgM circulation in those with recent or even
remote leptospirosis exposure. High titres of IgM may
be present in previously infected individuals even years
after the infection [6,11]. This could potentially explain
some of the MAT-positive/MAC ELISA-negative results
in acute phase sera [11].
Cross-reaction of our ELISA IgM assay with a leptospir-
osis-negative/HIV-positive serum was identified in this
study. HIV is one of the known pathogens that may cross-
react with leptospirosis on ELISA-IgM testing, in addition
to the other diseases included in our negative control
panel. Such cross-reactivity to non-leptospirosis disease is
a known drawback of ELISA-based assays [3]. The World
Health Organisation (WHO) recommends confirmatory
testing by MAT for this reason, although MAT may cross-
react with certain other pathogens also [3,24]. Pathogen
cross-reactivity could also have contributed to the low
specificity shown with our MAC ELISA-IgM assay,
particularly as the list of non-Leptospira infections in the
exclusion criteria was not exhaustive.
Previous validation studies of other leptospirosis ELISA-
IgM assays have shown variable sensitivities and specificities.
In Peru, an investigation of an outbreak of leptospirosis
in military recruits that used a commercial ELISA IgM
assay (PanBio Leptospira IgM ELISA, PanBio, Queensland,
Australia) demonstrated a paired sera sensitivity and spe-
cificity of 26% and 60%, respectively, when compared to
MAT [8]. In patients with MAT or culture confirmed
leptospirosis in Barbados, the PanBio ELISA-IgM assay
demonstrated a sensitivity and specificity of 87.5 and 96.4%
in the acute phase of illness. The same study evaluated a
second commercial ELISA-IgM assay (InDx IVD ELISA,
Integrated Diagnostics, Baltimore, MD, USA) with a sensi-
tivity and specificity of 89.6 and 92.7% in the acute phase of
illness [12]. An evaluation of IgM dot-ELISA dipstick, dip-
stick IgM assay and indirect haemagglutination assay by
comparison to MAT, culture or tissue immunohistochemis-
try was performed on sera from febrile patients in North
America, Hawaii, Puerto Rico, Palau and Thailand. In the
acute phase, all three methods performed poorly with sensi-
tivities of 50.0, 52.7 and 38.5% respectively. Overall paired
sera specificities were 98.8, 89.6 and 95.8% respectively [13].
Comparison of the performance of other ELISA-IgM
assays with this ELISA M20 MAC IgM assay is limited by
inter-laboratory variation in ‘gold standard’ serodiagnosis
(MAT) due to subjectivity in interpretation of agglutination
[12]. Moreover, there is considerable debate in the litera-
ture as to what constitutes a positive MAT titre, even in
leptospirosis-endemic countries. MAT titre cut-offs from
1:100 to 1:1600 have been used in the literature [2,25].
There were other limitations in this study, beyond the
assumption that MAT is a ‘gold standard’ method of
diagnosis. Additional limitations to this study include
delayed seroconversion after leptospirosis, which has
been well described. As many as 10% of patients will fail to
seroconvert within 30 days of the onset of symptoms [3],
and such cases may have been missed by either method of
serodiagnosis in this study. Finally, L. interrogans serovar
Copenhageni (M20) rabbit IgG antibody was unavailable
for use in this region at the time of the study, and this
would have been the ideal antibody to use in the ELISA
design.
Conclusion
The limited specificity and high sensitivity of the MAC-
ELISA IgM suggest that it would be most valuable as a
‘rule-out’ test, with confirmation of a positive test needed
by the more specific MAT at a reference laboratory, as per
the most recent WHO technical guidelines on the diagno-
sis of leptospirosis [24]. Thus, in developing countries such
as Peru, where access to reference serodiagnostic assays
like MAT may be difficult in many regions and limited
resources could preclude the purchase of commercial ELISA
assays, this in-house ELISA IgM assay may be useful to
‘rule-out’ a diagnosis of leptospirosis in the early stages of
febrile illness where timely initiation of anti-leptospiral
antibiotics may be critical [13].
This study highlights the limitations of using whole-cell
based enzyme immunoassays for leptospirosis diagnosis.
Rather than using total sonicated antigen, extraction
of particular candidate structural antigens, such as gly-
colipoprotein antigens, may improve specificity while
preserving sensitivity [25]. Recent advances in genomic,
proteomic, microarray and in-silico technologies may
also aid in the design of future generation serodiag-
nostic assays for this common and potentially fatal
infection [5,26-28].
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